$0.59
-0.05 (-7.29%)
Open$0.59
Previous Close$0.64
Day High$0.63
Day Low$0.55
52W High$4.38
52W Low$0.81
Volume—
Avg Volume138.0K
Market Cap4.63M
P/E Ratio—
EPS$-4.42
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,090.4% upside
Current
$0.59
$0.59
Target
$24.74
$24.74
$16.96
$24.74 avg
$28.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.58M | 4.80M | 3.77M |
| Net Income | 640.0K | 637.0K | 538.3K |
| Profit Margin | 14.0% | 13.3% | 14.3% |
| EBITDA | 1.20M | 1.08M | 968.7K |
| Free Cash Flow | 434.6K | 468.2K | 383.2K |
| Rev Growth | +11.7% | 0.0% | +15.1% |
| Debt/Equity | 0.17 | 0.18 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |